Clinical epidemiology · 2026
The Danish Lymphoid Cancer Research (DALY-CARE): Genetic Cohort Profile.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dietz Jojo Biel-Nielsen, Kadlec Tereza Fait, Rotbain Emelie Curovic, Werling Mikkel, Vainer Noomi, Katsimigas Andreas, Ostrowski Sisse Rye, Sørensen Erik, Pedersen Ole Birger Vesterager, Schwinn Michael, Nissen Janna, Magnusson Magnus Karl, Elhussein Hashim Hussein, Agius Rudi, Frederiksen Casper Møller, Rostgaard Klaus, Hjalgrim Henrik, Davidsson Olafur Birgir, Kristjánsson Ragnar Pétur, Brieghel Christian, Niemann Carsten Utoft
Аннотация
PURPOSE: The Danish Lymphoid Cancer Research (DALY-CARE) Genetic Cohort was established to support research into how genetic factors influence clinical outcomes in lymphoid cancers (LCs), including disease progression, treatment response, toxicity, and survival. Individual-level genetic data were combined with detailed clinical information from national health registers, hospital-based electronic health records (EHR), laboratory data, and pathology reports. The cohort enables large-scale studies of genetic susceptibility, disease course, and therapy-related outcomes in LCs and provides a platform for genetic epidemiology and future multi-omics research within a unified data infrastructure.
PARTICIPANTS: The genetic cohort includes 8675 genotyped individuals drawn from the broader DALY-CARE population (n=74,251, as of April 2025), including individuals diagnosed with LCs such as diffuse large B-cell lymphoma (DLBCL, n=1349), chronic lymphocytic leukemia (CLL, n=1245), multiple myeloma (MM, n=1209), follicular lymphoma (FL, n=704), Hodgkin lymphoma (HL, n=407), Waldenström macroglobulinemia and lymphoplasmacytic lymphoma (WM/LPL, n=368), marginal zone lymphoma (MZL, n=287), and precursor states such as monoclonal gammopathy of undetermined significance (MGUS, n=1299).
DESCRIPTIVE FINDINGS: Hematologic malignancy was the most frequent cause of death (30%), followed by infections (27%) and other cancers (15%). Polypharmacy, as a more sensitive proxy for comorbidity than hospital diagnosis codes, was substantial (median 7-8 drugs pre-diagnosis). Frequently observed comorbidities were hypertension (47%), cardiovascular disease (16%), cerebrovascular disease (11%) and type 2 diabetes (10%). Kinship analysis identified limited relatedness (41 parent-offspring, 51 siblings), while ancestry inference confirmed predominantly Northwestern European descent (97%).
FUTURE OPPORTUNITIES: The DALY-CARE Genetic Cohort provides a foundation for studying genetic and clinical determinants of LC outcomes. Integration of genotype data with EHR and national health registers enables exploration of germline risk and protective variants. Future expansions will integrate additional omics data types, such as whole-genome sequencing, transcriptomics, proteomics, and immunophenotyping, positioning the cohort as a national platform for multi-omics research in LC.
PARTICIPANTS: The genetic cohort includes 8675 genotyped individuals drawn from the broader DALY-CARE population (n=74,251, as of April 2025), including individuals diagnosed with LCs such as diffuse large B-cell lymphoma (DLBCL, n=1349), chronic lymphocytic leukemia (CLL, n=1245), multiple myeloma (MM, n=1209), follicular lymphoma (FL, n=704), Hodgkin lymphoma (HL, n=407), Waldenström macroglobulinemia and lymphoplasmacytic lymphoma (WM/LPL, n=368), marginal zone lymphoma (MZL, n=287), and precursor states such as monoclonal gammopathy of undetermined significance (MGUS, n=1299).
DESCRIPTIVE FINDINGS: Hematologic malignancy was the most frequent cause of death (30%), followed by infections (27%) and other cancers (15%). Polypharmacy, as a more sensitive proxy for comorbidity than hospital diagnosis codes, was substantial (median 7-8 drugs pre-diagnosis). Frequently observed comorbidities were hypertension (47%), cardiovascular disease (16%), cerebrovascular disease (11%) and type 2 diabetes (10%). Kinship analysis identified limited relatedness (41 parent-offspring, 51 siblings), while ancestry inference confirmed predominantly Northwestern European descent (97%).
FUTURE OPPORTUNITIES: The DALY-CARE Genetic Cohort provides a foundation for studying genetic and clinical determinants of LC outcomes. Integration of genotype data with EHR and national health registers enables exploration of germline risk and protective variants. Future expansions will integrate additional omics data types, such as whole-genome sequencing, transcriptomics, proteomics, and immunophenotyping, positioning the cohort as a national platform for multi-omics research in LC.